The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: A new pharmacodynamic marker?

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Pantano, Francesco ^a   Santoni, Matteo ^b   Procopio, Giuseppe ^c   Rizzo, Mimma ^d   Iacovelli, Roberto ^e   Porta, Camillo ^f   Conti, Alessandro ^b   Lugini, Antonio ^g   Milella, Michele ^h   Galli, Luca ⁱ   Ortega, Cinzia ^j   Guida, Francesco Maria ^a   Silletta, Marianna ^a   Schinzari, Giovanni ^k   Verzoni, Elena ^c   Modica, Daniela ^e   Crucitti, Pierfilippo ^a   Rauco, Annamaria ^g   Felici, Alessandra ^h   Ballatore, Valentina ^j   Cascinu, Stefano ^b   Tonini, Giuseppe ^a   Carteni, Giacomo ^d   Russo, Antonio ^l   Santini, Daniele ^a   more..

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d CARDARELLI HOSPITAL   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PISA   (Italy)

^j CANDIOLO CANCER INSTITUTE   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

^l UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; EVEROLIMUS; GLUCOSE; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; CANCER CHEMOTHERAPY; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CORRELATIONAL STUDY; DIET RESTRICTION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHARMACODYNAMICS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; ADOLESCENT; ANALYSIS; BLOOD; CANCER STAGING; CARCINOMA, RENAL CELL; DISEASE COURSE; KIDNEY NEOPLASMS; METABOLISM; MORTALITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL RATE; YOUNG ADULT;

MAMMALIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BIOMARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CARCINOMA, RENAL CELL; CHOLESTEROL; DISEASE PROGRESSION; EVEROLIMUS; HUMANS; KIDNEY NEOPLASMS; LIPID METABOLISM; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRIGLYCERIDES; YOUNG ADULT;

EID: 84929493881     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120427     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90. doi: 10.3322/caac.20107 PMID: 21296855
2. Singer EA, Gupta GN, Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol. 2012; 24: 284-290. doi: 10.1097/CCO.0b013e328351c646 PMID: 22343386
3. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008; 372: 449-456. doi: 10.1016/S0140-6736(08)61039-9 PMID: 18653228
4. Figlin RA, Calvo E, Motzer RJ, Hutson TE, Oudard S, Porta C, et al. Everolimus in metastatic renal cell carcinoma (mRCC): Subgroup analysis of patients (pts) with one versus two prior vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) therapies enrolled in the phase III RECORD-1 study. J Clin Oncol. 2011; 29: suppl 7; abstr 304.
5. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002; 22: 7004-7014. PMID: 12242281
6. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin WG Jr. TSC2 regulates VEGF through mTOR-dependent and-independent pathways. Cancer Cell. 2003; 4: 147-158. PMID: 12957289
7. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res. 2004; 10: 6290S-6295S. PMID: 15448019
8. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol. 2005; 16: 29-37. PMID: 15659337
9. Kim WY, Kaelin WG Jr. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004; 22: 4991-5004. PMID: 15611513
10. Tokunaga C, Yoshino K, Yonezawa K. mTOR integrates amino acid- and energy-sensing pathways. Biochem Biophys Res Commun. 2004; 313: 443-446. PMID: 14684182
11. Fujita S, Dreyer HC, Drummond MJ, Glynn EL, Cadenas JG, Yoshizawa F, et al. Nutrient signalling in the regulation of human muscle protein synthesis. J Physiol. 2007; 582: 813-823. PMID: 17478528
12. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010; 7: 277-285. doi: 10.1038/nrurol.2010.47 PMID: 20448661
13. Soliman GA. The integral role of mTOR in lipid metabolism. Cell Cycle. 2011; 10: 861-862. PMID: 21325894
14. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441: 424-430. PMID: 16724053
15. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124: 471-484. PMID: 16469695
16. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The mTOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets. 2010; 10: 484-495. PMID: 20384580
17. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin RA, Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281. PMID: 17538086
18. Kasiske BL, De Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant. 2008; 8: 1384-1392. doi: 10.1111/j.1600-6143.2008.02272.x PMID: 18510633
19. Hartford CM, Desai AA, Janisch L, Karrison T, Rivera VM, Berk L, et al. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009; 15: 1428-1434. doi: 10.1158/1078-0432.CCR-08-2076 PMID: 19228743
20. Michaelson MD, Stadler WM. Predictive markers in advanced renal cell carcinoma. Semin Oncol. 2013; 40: 459-464. doi: 10.1053/j.seminoncol.2013.05.001 PMID: 23972709
21. Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G, et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res. 2012; 18: 3188-3196. doi: 10.1158/1078-0432.CCR-11-3137 PMID: 22472176
22. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med. 2006; 23: 469-480. PMID: 16681555
23. Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, et al. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012; 18: 1-78. PMID: 22522068
24. WHO CRITERIA 2000. The International Classification of adult underweight, overweight and obesity According to BMI.
25. Tokunaga C, Yoshino K, Yonezawa K. mTOR integrates amino acid and energy-sensing pathways. Biochem Biophys Res Commun. 2004; 313: 443-446. PMID: 14684182
26. Fujita S, Dreyer HC, Drummond MJ, Glynn EL, Cadenas JG, Yoshizawa F, et al. Nutrient signalling in the regulation of human muscle protein synthesis. J Physiol 2007; 582: 813-823. PMID: 17478528
27. Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010; 7: 277-285. doi: 10.1038/nrurol.2010.47 PMID: 20448661
28. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008; 8: 224-236. doi: 10.1016/j.cmet.2008.07.007 PMID: 18762023
29. Düvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010; 39: 171-183. doi: 10.1016/j.molcel.2010.06.022 PMID: 20670887
30. Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, et al. Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther. 2010; 9: 2770-2784. doi: 10.1158/1535-7163.MCT-09-0980 PMID: 20876744
31. Gebhard RL, Clayman RV, Prigge WF, Figenshau R, Staley NA, Reesey C, et al. Abnormal cholesterol metabolism in renal clear cell carcinoma. J Lipid Res 1987; 28: 1177-84. PMID: 3681141
32. Drabkin HA, Gemmill RM. Obesity, cholesterol, and clear-cell renal cell carcinoma (RCC). Adv Cancer Res. 2010; 107: 39-56. doi: 10.1016/S0065-230X(10)07002-8 PMID: 20399960
33. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256-4265. doi: 10.1002/cncr.25219 PMID: 20549832
34. Wang BT, Ducker GS, Barczak AJ, Barbeau R, Erle DJ, Shokat KM. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci U S A. 2011; 108: 15201-15206. doi: 10.1073/pnas.1103746108 PMID: 21876130
35. Ma KL, Varghese Z, Ku Y, Powis SH, Chen Y, Moorhead JF, et al. Sirolimus inhibits endogenous cholesterol synthesis induced by inflammatory stress in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2010; 298: H1646-1651. doi: 10.1152/ajpheart.00492.2009 PMID: 20348217
36. Gueguen Y, Ferrari L, Souidi M, Batt AM, Lutton C, Siest G, et al. Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. Basic Clin Pharmacol Toxicol. 2007; 100: 392-397. PMID: 17516993
37. Sharpe LJ, Brown AJ. Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochem Biophys Res Commun. 2008; 373: 670-674. doi: 10.1016/j.bbrc.2008.06.108 PMID: 18602894
38. Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J. Prevention of atherosclerosis by the mTOR Inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis. 2008; 198: 39-48. PMID: 17980369
39. Cho DC, Atkins MB. Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon? Clin Cancer Res. 2012; 18: 2999-3001. doi: 10.1158/1078-0432.CCR-12-0953 PMID: 22508855
40. Setiawan VW, Stram DO, Nomura AM, Kolonel LN, Henderson BE. Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol. 2007; 166: 932-940. PMID: 17656615
41. Zhang C, Yu L, Xu T, Hao Y, Zhang X, Liu Z, et al. Association of dyslipidemia with renal cell carcinoma: a 1: 2 matched case-control study. PLoS One. 2013; 8: e59796. doi: 10.1371/journal.pone.0059796 PMID: 23536888
42. Rolfo C, Bronte G, Sortino G, Papadimitriou K, Passiglia F, Fiorentino E, et al. The role of targeted therapy for gastrointestinal tumors. Expert Rev Gastroenterol Hepatol. 2014; 8: 875-885. doi: 10.1586/17474124.2014.922870 PMID: 24957206
43. Bronte F, Bronte G, Cusenza S, Fiorentino E, Rolfo C, Cicero G, et al. Targeted therapies in hepatocellular carcinoma. Curr Med Chem. 2014; 21: 966-974. PMID: 23992323
44. Rolfo C, Giovannetti E, Hong DS, Bivona T, Raez LE, Bronte G, et al. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014; 40: 990-1004. doi: 10.1016/j.ctrv.2014.05.009 PMID: 24953979